curacle co.,ltd. (KOSDAQ: 365270)

Market Cap	84.08B
Revenue (ttm)	1.77B
Net Income (ttm)	-16.49B
Shares Out	13.87M
EPS (ttm)	-1,190.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	57,985
Average Volume	108,012
Open	6,020.00
Previous Close	6,060.00
Day's Range	5,960.00 - 6,100.00
52-Week Range	4,900.00 - 21,350.00
Beta	1.51
RSI	47.30
Earnings Date	n/a

About curacle co.,ltd.

Curacle Co., Ltd., a bio-venture business, engages in the research and development of drugs for diseases caused by aging process and damage to blood vessels. Its products cover age-related vascular diseases, intractable metabolic diseases, and cancer targeting/immunotherapy. The company’s products in pipeline include CU06, which covers treatment and medical indications, such as diabetic macular edema/retinopathy, acute respiratory distress syndrome, myocardial infarction, stroke treatment, concomitantly used with immunotherapy, inflammatory bow...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 365270

Financial Performance

In 2023, curacle co.,ltd.'s revenue was 10.29 billion, an increase of 187.32% compared to the previous year's 3.58 billion. Losses were -11.59 billion, 1.58% more than in 2022.